STOCK TITAN

Jeffrey Bezos-Linked Explore Reports 1.04M Shares (5.4%) in Lyell

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Lyell Immunopharma, Inc. Schedule 13G reports that Explore Investments LLC and Jeffrey P. Bezos each may be deemed to beneficially own 1,040,964 shares of Lyell common stock, representing 5.4% of the outstanding class as of the Event Date. Explore is the direct holder and Mr. Bezos is the sole member of Explore. Of the shares reported, 938,438 were acquired in the initial closing of a private placement on the Event Date. The filing notes the calculation basis of 14,808,006 total shares outstanding and disclaims beneficial ownership beyond the shares reported.

Positive

  • Disclosure of 1,040,964 shares (5.4%) provides clear transparency on a significant holder
  • Identifies source of holdings including 938,438 shares acquired in the PIPE initial closing
  • Filing follows Schedule 13G format and includes calculation basis of 14,808,006 shares outstanding

Negative

  • None.

Insights

TL;DR: A single investor vehicle and its sole member report a 5.4% stake after a PIPE purchase, a potentially material passive stake.

The filing documents a passive stake of 1,040,964 shares equal to 5.4% of Lyell's common stock, calculated on 14,808,006 shares outstanding after recent issuances. The position includes 938,438 shares acquired in the PIPE initial closing. The Schedule 13G certification indicates the shares were not acquired to influence control, consistent with passive reporting. This disclosure is important for shareholder ownership concentration and may affect liquidity and block trade dynamics but contains no operational or financial performance data.

TL;DR: Disclosure shows a disclosed passive investor exceeding 5% threshold, triggering required public reporting without claiming control.

The statement clarifies Explore Investments LLC as the direct holder and Jeffrey P. Bezos as the sole member, which explains joint reporting. The filing expressly disclaims any intent to influence control and follows Form 13G standards for passive investors. It references related PIPE documentation and rights but does not assert control or group arrangements. This transparency satisfies SEC ownership disclosure norms and informs other stakeholders of a significant passive holder.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934 (as amended, the "Exchange Act") and based on an aggregate total of 14,808,006 shares of the common stock of Lyell Pharmaceuticals, Inc. (the "Issuer") outstanding as of May 30, 2025, as reported by the Issuer in its preliminary prospectus (the "Prospectus") (File No. 333-288769) dated July 18, 2025, incorporated in the Issuer's Form S-3 registration statement filed with the Securities and Exchange Commission (the "SEC") on July 18, 2025, and after giving effect to the issuance of: (i) an additional 625,000 shares (the "ImmPACT Shares") of common stock on July 2, 2025 as reported in the Prospectus and (ii) an additional 3,753,752 shares (the "PIPE Shares") of common stock on July 25, 2025 upon completion of the Issuer's private placement transaction as reported by the Issuer in its Current Report filed with the SEC on Form 8-K (File No. 001-40502) on July 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: For purposes of Rule 13d-3 under the Exchange Act, all shares of the Issuer's common stock held by Explore may be deemed to be beneficially owned by Jeffrey P. Bezos as the sole member of Explore. The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act, and based on an aggregate total of 14,808,006 shares of the common stock of the Issuer outstanding as of May 30, 2025, as reported in the Prospectus, and after giving effect to the issuance of: (i) the ImmPACT Shares on July 2, 2025 as reported in the Prospectus and (ii) the PIPE Shares on July 25, 2025, as reported by the Issuer in its Current Report filed with the SEC on Form 8-K (File No. 001-40502) on July 25, 2025.


SCHEDULE 13G



Explore Investments LLC
Signature:/s/ Paul Dauber
Name/Title:Paul Dauber/its Manager
Date:08/19/2025
Jeffrey P. Bezos
Signature:/s/ Jeffrey P. Bezos
Name/Title:Jeffrey P. Bezos/an Individual
Date:08/19/2025

FAQ

How many Lyell (LYEL) shares do Explore Investments LLC and Jeffrey P. Bezos report owning?

They each may be deemed to beneficially own 1,040,964 shares, representing 5.4% of the outstanding common stock as reported.

What portion of the reported stake was acquired in the PIPE transaction?

938,438 shares of the reported holdings were acquired in connection with the initial closing of the PIPE transaction on the Event Date.

What share count did the filing use to calculate the 5.4% ownership?

The percentage is based on an aggregate total of 14,808,006 shares outstanding as of May 30, 2025, as stated in the Prospectus and after specified issuances.

Does the Schedule 13G indicate the holders intend to influence control of Lyell?

No. The certification states the securities were not acquired to change or influence control and the filing is submitted under Schedule 13G standards for passive investors.

Who is the direct holder of the reported shares and what is Jeffrey P. Bezos's relation?

Explore Investments LLC is the direct holder and Jeffrey P. Bezos is identified as the sole member of Explore, so he may be deemed to beneficially own the shares.